S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
NYSE:GKOS

Glaukos (GKOS) Stock Price, News & Analysis

$92.69
+2.99 (+3.33%)
(As of 03/27/2024 ET)
Today's Range
$89.62
$92.70
50-Day Range
$84.31
$96.42
52-Week Range
$45.38
$97.24
Volume
452,668 shs
Average Volume
504,173 shs
Market Capitalization
$4.59 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$96.30

Glaukos MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.78 Rating Score
Upside/​Downside
3.9% Upside
$96.30 Price Target
Short Interest
Bearish
7.40% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.90
Upright™ Environmental Score
News Sentiment
0.33mentions of Glaukos in the last 14 days
Based on 14 Articles This Week
Insider Trading
Selling Shares
$22.11 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.18) to ($1.36) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.66 out of 5 stars

Medical Sector

465th out of 939 stocks

Surgical & Medical Instruments Industry

54th out of 98 stocks

GKOS stock logo

About Glaukos Stock (NYSE:GKOS)

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, an implantable device intended to reduce the intraocular pressure of the eye; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo California.

GKOS Stock Price History

GKOS Stock News Headlines

Glaukos (NYSE:GKOS) Price Target Raised to $120.00
Claim Your Complimentary Bitcoin Reward
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.
Glaukos (NYSE:GKOS) Trading Up 2.4%
Glaukos (NYSE:GKOS) Receives "Buy" Rating from Truist Financial
Claim Your Complimentary Bitcoin Reward
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.
Truist Financial Reaffirms Their Buy Rating on Glaukos (GKOS)
5 Analysts Have This To Say About Glaukos
GKOS Apr 2024 140.000 call
GKOS Apr 2024 92.500 put
GKOS Apr 2024 80.000 put
Glaukos Corp Director Mark Foley Sells 4,560 Shares
Glaukos Stock (NYSE:GKOS), Short Interest Report
GKOS Apr 2024 47.500 put
See More Headlines
Receive GKOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Glaukos and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/21/2024
Today
3/28/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Employees
783
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$96.30
High Stock Price Target
$120.00
Low Stock Price Target
$65.00
Potential Upside/Downside
+3.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
9 Analysts

Profitability

Net Income
$-134,660,000.00
Pretax Margin
-42.49%

Debt

Sales & Book Value

Annual Sales
$314.71 million
Book Value
$9.46 per share

Miscellaneous

Free Float
45,611,000
Market Cap
$4.59 billion
Optionable
Optionable
Beta
1.08
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives


GKOS Stock Analysis - Frequently Asked Questions

Should I buy or sell Glaukos stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Glaukos in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" GKOS shares.
View GKOS analyst ratings
or view top-rated stocks.

What is Glaukos' stock price target for 2024?

9 Wall Street research analysts have issued twelve-month target prices for Glaukos' shares. Their GKOS share price targets range from $65.00 to $120.00. On average, they expect the company's share price to reach $96.30 in the next twelve months. This suggests a possible upside of 3.9% from the stock's current price.
View analysts price targets for GKOS
or view top-rated stocks among Wall Street analysts.

How have GKOS shares performed in 2024?

Glaukos' stock was trading at $79.49 at the beginning of the year. Since then, GKOS shares have increased by 16.6% and is now trading at $92.69.
View the best growth stocks for 2024 here
.

Are investors shorting Glaukos?

Glaukos saw a drop in short interest during the month of February. As of February 15th, there was short interest totaling 3,630,000 shares, a drop of 8.6% from the January 31st total of 3,970,000 shares. Based on an average daily volume of 829,900 shares, the days-to-cover ratio is currently 4.4 days.
View Glaukos' Short Interest
.

When is Glaukos' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our GKOS earnings forecast
.

How were Glaukos' earnings last quarter?

Glaukos Co. (NYSE:GKOS) posted its earnings results on Wednesday, February, 21st. The medical instruments supplier reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.56) by $0.07. The medical instruments supplier earned $82.40 million during the quarter, compared to the consensus estimate of $81 million. Glaukos had a negative net margin of 42.79% and a negative trailing twelve-month return on equity of 22.67%. The firm's revenue was up 15.7% compared to the same quarter last year. During the same quarter last year, the business posted ($0.53) EPS.

What guidance has Glaukos issued on next quarter's earnings?

Glaukos updated its FY 2024 earnings guidance on Friday, February, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $350.0 million-$360.0 million, compared to the consensus revenue estimate of $352.7 million.

What is Thomas W. Burns' approval rating as Glaukos' CEO?

10 employees have rated Glaukos Chief Executive Officer Thomas W. Burns on Glassdoor.com. Thomas W. Burns has an approval rating of 100% among the company's employees. This puts Thomas W. Burns in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Glaukos own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Glaukos investors own include NVIDIA (NVDA), Marvell Technology (MRVL), PTC Therapeutics (PTCT), PayPal (PYPL), QUALCOMM (QCOM), Alibaba Group (BABA), Teladoc Health (TDOC), Intel (INTC), Advanced Micro Devices (AMD) and Boeing (BA).

When did Glaukos IPO?

Glaukos (GKOS) raised $76 million in an initial public offering on Thursday, June 25th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs served as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers.

Who are Glaukos' major shareholders?

Glaukos' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (10.73%), Vanguard Group Inc. (10.59%), Brown Capital Management LLC (5.53%), Wellington Management Group LLP (2.71%), Artisan Partners Limited Partnership (2.51%) and Dimensional Fund Advisors LP (1.89%). Insiders that own company stock include Alex R Thurman, Gilbert H Kliman, Joseph E Gilliam, Joseph E Gilliam, Marc Stapley, Mark J Foley and Thomas William Burns.
View institutional ownership trends
.

How do I buy shares of Glaukos?

Shares of GKOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:GKOS) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners